Here's the latest broker upgrades on ASX All Ords shares

The latest round of broker upgrades on ASX All Ords shares are here and you may as well strap in because there's a few names to discuss.

Brokers are bullish on companies ranging from the healthcare sector, to energy, to food, giving investors a good selection of meat to choose from.

Here's a closer look.

ASX All Ords shares in favour: Pro Medicus Ltd (ASX: PME)

Bell Potter doubled its price target on Pro Medicus shares in a note to clients this week, lifting it from $130 to $260, according to The Australian.

The health imaging software leader has recently signed its largest deal ever regarding its Visage system, valued at $330 million.

"We have previously under appreciated the value accretion in contract upgrades", Bell Potter said.

"Contract wins are likely to continue", it added.

Pro Medicus shares were last trading at $264.61 apiece.

ALS Ltd (ASX: ALQ)

ALS was started with a buy rating from Bell Potter with a price target of $17.30. Analysts said ALS is well-positioned to benefit from global demand for laboratory testing services.

The broker sees "compelling value" in the business, including its "capital allocation framework", which has produced over 15% returns on capital employed (ROCE).

At the time of writing, the ASX All Ords share is priced at $15.97 apiece, leaving an 8% upside potential from Bell's price target.

Boss Energy Ltd (ASX: BOE)

Meanwhile, Citi has initiated coverage on Boss Energy with a buy rating this week and a $3.40 price target.

With Boss shares trading at $2.65 apiece at the time of writing, the broker sees 28% upside potential from here.

Tribeca Investment Partners also likes the ASX All Ords share, noting the scaling global demand for nuclear energy.

This has been driven in part by recent investment in artificial intelligence (AI)- related ventures, such as data centres.

The firm says we are at the cusp of "a new energy paradigm", putting companies like Boss centre stage.

Integral Diagnostics Ltd (ASX: IDX)

Bell Potter has also upgraded Integral Diagnostics to a buy with a target price of $3.87.

The medical imaging company's share price has grown by 63% this year, currently resting at $3.11 apiece.

The ASX All Ords share is also rated a buy from consensus, according to CommSec.

Collins Foods Ltd (ASX: CKF)

Citi has also elevated Collins Foods to a buy with a target price of $9.38, following the lead of analysts at Morgans, who have a buy rating and a $10.50 valuation.

The operator of KFC and Taco Bell franchises in Australia is navigating the inflationary blizzard, but its half-year results were slightly better than expected.

Zooming out, shares are down 31% this year, last trading at $8.10 apiece.

Steadfast Group Ltd (ASX: SDF)

Finally, Bell Potter upgraded Steadfast Group to a buy with a new price target of $6.50 this week.

The broker joins the consensus of analyst estimates, which also rates the insurance brokerage a buy.

The ASX All Ords share has an extensive history of dividend growth, increasing the payment from 0.07 cents per share in FY18 to 17.1 cents in the last 12 months.

ASX All Ords shares takeout

Analysts have upgraded these ASX All Ords shares to buys this week. Time will tell which succeed and which don't.

The post Here's the latest broker upgrades on ASX All Ords shares appeared first on The Motley Fool Australia.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Steadfast Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Steadfast Group. The Motley Fool Australia has recommended Collins Foods, Integral Diagnostics, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2024